Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBIT (2016 - 2025)

Historic EBIT for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$19.2 million.

  • Avalo Therapeutics' EBIT fell 4927.3% to -$19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.5 million, marking a year-over-year decrease of 577.94%. This contributed to the annual value of -$68.5 million for FY2024, which is 15049.18% down from last year.
  • As of Q3 2025, Avalo Therapeutics' EBIT stood at -$19.2 million, which was down 4927.3% from -$19.3 million recorded in Q2 2025.
  • Avalo Therapeutics' 5-year EBIT high stood at $4.1 million for Q3 2022, and its period low was -$32.8 million during Q1 2024.
  • For the 5-year period, Avalo Therapeutics' EBIT averaged around -$14.1 million, with its median value being -$13.3 million (2024).
  • Per our database at Business Quant, Avalo Therapeutics' EBIT skyrocketed by 12487.4% in 2022 and then tumbled by 27269.11% in 2024.
  • Over the past 5 years, Avalo Therapeutics' EBIT (Quarter) stood at -$18.0 million in 2021, then soared by 50.7% to -$8.9 million in 2022, then increased by 13.52% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then tumbled by 44.23% to -$19.2 million in 2025.
  • Its last three reported values are -$19.2 million in Q3 2025, -$19.3 million for Q2 2025, and -$14.7 million during Q1 2025.